Oncogene Profiling Services
Creative Biolabs provides a multi-faceted genomic deep dive using advanced NGS and transcriptomics. We deliver high-confidence data on all critical oncogenic alterations, including fusions, copy number variants, and immune-oncology biomarkers (TMB/MSI). Clients gain the ability to rapidly validate novel targets, precisely stratify research cohorts, and non-invasively monitor compound resistance, accelerating their drug discovery and preclinical development timelines.
Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Oncogene Profiling: The Genomic Imperative in Cancer Research
Cancer is fundamentally a disease of the genome, driven by uncontrolled proliferation stemming from acquired genetic alterations. The success of modern therapeutic strategies - from targeted small molecules to advanced immunotherapies - hinges on the precise identification of actionable oncogenes. These driver mutations are the engine of oncogenesis. Identifying them is the critical first step in defining research cohorts for validation studies and guiding target prioritization. Without comprehensive, high-resolution profiling, drug development efforts navigate in the dark.
To explore our comprehensive capabilities, we invite you to request a formal consultation.
What We Can Offer
Creative Biolabs offers a modular suite of services to fit your specific research needs, from deep sequencing of solid tumors to ultra-sensitive liquid biopsy.
Oncogene Mutation & Copy Number Alteration Analysis
This core service uses DNA-based NGS to detect single nucleotide variants (SNVs), small Insertions/Deletions (Indels), and copy-number alterations (CNAs), including amplifications and deletions, across hundreds of cancer-relevant genes. This is essential for identifying the primary driver mutations and tumor suppressor loss.
Learn More →
Oncogene Fusion & Structural Variant Detection
Utilizing RNA-based sequencing (transcriptomic profiling), this service is dedicated to the high-confidence detection of clinically relevant fusion genes (e.g., ALK, ROS1, RET). It also provides critical insight into the expression level and functional isoforms of oncogenes.
Learn More →
Oncogene Expression & Isoform Profiling
Beyond simple detection, this RNA-focused analysis quantifies the expression levels of key oncogenes and their corresponding isoforms. This is vital for understanding gene regulatory networks and validating the functional impact of identified genomic alterations.
Learn More →
Oncogene Pathway Activity Analysis
This advanced module uses integrated DNA/RNA data to infer the activity status of major cancer signaling pathways (e.g., RAS/MAPK, PI3K/AKT). This provides a functional context for the individual genomic alterations, aiding in the selection of drug combinations.
Learn More →
How Creative Biolabs Can Assist Your Project
Highlights
Integrated Multi-Modal Analysis
Seamless, single-workflow analysis combining DNA, RNA, and ctDNA (liquid biopsy) to ensure no actionable mutation, fusion gene, or resistance mechanism is missed.
Actionable Biomarker Suite
Beyond driver mutations (SNVs/CNAs), we concurrently profile key immune-oncology biomarkers, including tumor mutation burden (TMB) and microsatellite instability (MSI) status, to guide research model selection for immune-oncology studies.
Customization and Flexibility
Creative Biolabs offers fully customized panel design and validation, allowing the integration of your proprietary or novel research targets and specific chromosomal structural variants into the core profiling assay.
Robust Sample Handling
Specialized, validated protocols optimized for analyzing challenging, low-purity clinical specimens, including degraded FFPE tissue and precious liquid biopsy plasma.
To fully understand the Creative Biolabs advantage, we invite you to request a project quotation.
Customer Reviews
-
Streamlined Enrollment
The integration of Creative Biolabs' services into our research framework has significantly enhanced our capacity for the high-confidence identification of rare, actionable fusion transcripts. This critical technical advantage has directly expedited the research cohort selection process for our basket trial design. - J**n S**h.
-
High Sensitivity
Using Creative Biolabs' services in our research has significantly improved our ability to detect resistance-conferring mutations at ultra-low variant allele frequencies (VAF) in liquid biopsy, providing crucial data for our next-gen inhibitor development. - L*a M**r.
FAQs
What is the main advantage of using Creative Biolabs' multi-modal approach (DNA, RNA, ctDNA) over a standard DNA-only panel?
A DNA-only panel will miss critical, actionable information like fusion genes, which require RNA (transcriptomic profiling) for definitive detection, and it lacks the sensitivity to non-invasively track disease via ctDNA. Our integrated approach ensures maximum information retrieval from a single sample, leading to more informed research decisions and robust study design.
Our samples are primarily FFPE tissue with low tumor purity. Can your service still deliver accurate results?
Yes. Our protocols are specifically optimized for challenging FFPE samples, which are common in research settings. We utilize unique molecular counters and a high-depth sequencing strategy combined with sophisticated bioinformatics, enabling us to accurately detect variants at high sensitivity even from low-purity input.
Related Services
How to Contact Us
Creative Biolabs' oncogene profiling services are your strategic choice for comprehensive, high-resolution, and research-validated genomic analysis. We are ready to discuss your unique project needs and demonstrate how our technical expertise can be applied to your specific challenges. Please contact us.
For Research Use Only | Not For Clinical Use
Download our brochure